Search

Your search keyword '"Zannad, F."' showing total 1,982 results

Search Constraints

Start Over You searched for: Author "Zannad, F." Remove constraint Author: "Zannad, F."
1,982 results on '"Zannad, F."'

Search Results

151. Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study

152. Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction

155. High-sensitivity C-reactive Protein, Low-Density Lipoprotein Cholesterol, and Cardiovascular Outcomes in Patients with Type 2 Diabetes in the EXAMINE (Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care) Trial

156. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis

157. Determinants and clinical outcome of uptitration of ACE-inhibitor and beta-blocker in patients with heart failure: a prospective European study

158. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial

159. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure - Proposal of a novel mechanism of action

160. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF

161. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

162. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

163. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

164. Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure

166. The potential role and rationale for treatment of heart failure with sodium–glucose co-transporter 2 inhibitors

167. The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology

168. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: A prospective European study

169. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis

174. Low cardiac fibrosis biomarkers levels predict cardiac resynchronization therapy response

175. Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan Trial)

176. 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*

179. Adaptive Servo-Ventilation For Central Sleep Apnea In Systolic Heart Failure: Psg Data From The Serve-Hf Major Substudy

180. Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990-2013: findings from the Global Burden of Disease Study 2013

181. The autonomic nervous system as a therapeutic target in heart failure: A scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology

185. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

186. Risk score for incident heart failure: a subject-level meta-analysis from the Heart 'Omics' in Ageing (HOMAGE) database

188. Erratum: 'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)

189. Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome

190. Plasma fibroblast growth factor 23 is associated with poor outcome and unsuccessful uptitration of guideline-recommended pharmacotherapy in patients with worsening heart failure

191. A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

192. Linee guida ESC 2015 per il trattamento dei pazienti con aritmie ventricolari e la prevenzione della morte cardiaca improvvisa: Task Force per il Trattamento dei Pazienti con Aritmie Ventricolari e la Prevenzione della Morte Cardiaca Improvvisa della Società Europea di Cardiologia (ESC)

195. Prevention of cardiovascular disease guided by total risk estimations − challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy

196. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

197. Co-morbidities in Heart Failure, An Issue of Heart Failure Clinics,

198. Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial

Catalog

Books, media, physical & digital resources